Please login to the form below

Cx601

This page shows the latest Cx601 news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Alofisel - previously Cx601 - is approved to treat complex perianal fistulas in adult patients with nonactive or mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at

Latest news

Takeda offers €520m for stem cell firm TiGenix

CX601 has been classed as an orphan treatment for treating people who don’t respond to drug therapy. ... offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”.
CHMP backs Europe’s first allogeneic stem cell therapy

Takeda paid 25m upfront for rights to Cx601 for this indication outside the US, pledging another 355m in milestone payments, including 15m on approval by the EMA. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for
TiGenix’s Crohn's fistulas treatment wins orphan drug status

The drug - currently known as Cx601 - could potentially treat ‘complex’ perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... Meanwhile, TiGenix and partner Takeda has
TiGenix cell therapy for Crohn's fistulas shows long-term benefit

In ADMIRE-CD, 56% of patients treated with Cx601 and usual supportive care went into remission, compared to 39% of patients who received placebo plus standard care. ... Existing therapies are limited and associated with complications and a high failure

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

authorisation for Cx601, so it was probably a good time for Takeda to make a move. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally administered for treatment of
Deal Watch July 2016

Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

TiGenix appoints Dr Marie Paule Richard

In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Copywriter: Salary TBC

Senior Medical Writer: Salary TBC

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Account Director, Medical Education: Salary TBC

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Subscribe to our email news alerts

PMHub

Add my company

Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...